Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).
Miyawaki M, Naoki K, Yoda S, Nakayama S, Satomi R, Sato T, Ikemura S, Ohgino K, Ishioka K, Arai D, Namkoong H, Otsuka K, Miyazaki M, Tani T, Kuroda A, Nishino M, Yasuda H, Kawada I, Koh H, Nakamura M, Terashima T, Sakamaki F, Sayama K, Betsuyaku T, Soejima K.
Miyawaki M, et al. Among authors: kuroda a.
Mol Clin Oncol. 2017 Mar;6(3):409-414. doi: 10.3892/mco.2017.1154. Epub 2017 Feb 6.
Mol Clin Oncol. 2017.
PMID: 28451422
Free PMC article.